Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News SpePharm and JHP acquire Dantrium from Procter and Gamble

SpePharm and JHP acquire Dantrium from Procter and Gamble

27th August 2008

SpePharm and JHP Pharmaceuticals have together purchased the global rights to Dantrium (dantrolene sodium) from Procter & Gamble.

Dantrium is administered intravenously as a treatment for malignan hyperthermia, which can be a life-threatening reaction to some gaseous anaesthetics.

It can be given orally for the control of clinical spasticity which results from spinal cord injury, stroke, multiple sclerosis, cerebral palsy or other upper motor neuron disorders.

The compound has been acquired by JHP Pharmaceuticals in the US and Canada with the firm also purchasing the supply rights in Australia, Chile, Israel and New Zealand, with SpePharm buying all other global rights.

Jean-Francois Labbe, chief executive officer of SpePharm, said: “We have been pleased to partner with JHP in this acquisition and secure Procter & Gamble’s rights to Dantrium in the rest of the world – excluding the JHP territories.”

He added the product will receive support in Europe from the company’s growing marketing and hospital sales infrastructure.

Stuart Hinchen, president of JHP said Dantrium would fit well into its existing product portfolio.

In February 2008, SpePharm announced the receipt of marketing authorisation of Loramyc in the UK, Belgium and Denmark as a treatment for oropharyngeal candidiases in immuno-compromised patients.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.